Pharvaris N.V.
PHVSHealthcareNASDAQBiotechnology
Scan Results
Daily timeframePharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other. The company carries a $2.21B market cap, placing it firmly in the mid-cap category. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant.
Market Cap
$2.21B
Beta
-2.46
P/E (TTM)
—
P/E (Fwd)
-10.27
EPS (TTM)
$-3.06
EPS (Fwd)
$-3.06
ROE
-70.5%
ROA
-42.3%
Cash
$318.3M
Total Debt
$673,728
Free CF
-$90.4M
52W Change
37.6%
Annual Financials
Cash vs Debt
Where PHVS stands vs its 150-day and 200-day moving averages
As of the October 19, 2026 close, PHVS finished 13.34% below its 150-day moving average ($32.01) and 9.64% below its 200-day moving average ($30.70). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is PHVS overbought or oversold?
At the October 19, 2026 close, PHVS's RSI(14) was 19.8, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Pharvaris N.V. holds $318.3M in cash against $674K in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. The company is burning cash, with free cash flow at -$90.4M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -70.5% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
PHVS's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. With cash comfortably exceeding debt, PHVS has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing PHVS.